Company: MYGN
Filing Date: 2025-06-05
Form Type: 8-K
Source: 0000899923-25-000066
Chunk: 0

Company: MYRIAD GENETICS INC
Filing Date: 2025-06-05
Form: 8-K
Item: Item 5.02
Chunk 0
---
ITEM 5.02 Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

As reported below in Item 5.07, Myriad Genetics, Inc. (the “ Company”) held its 2025 Annual Meeting of Stockholders (the “ Annual Meeting”), at which the Company's stockholders approved an amendment to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2017 Plan”), which increased the aggregate number of shares of common stock available for the grant of awards under the 2017 Plan by an additional 6.5 million shares.

Additionally, on June 5, 2025, the Board of Directors (the “ Board”) of the Company approved an amendment to Section 4(c)(i) of the 2017 Plan to increase the cap on the number of shares to be issued in any fiscal year from 500,000 shares to 574,040 shares of common stock.

A summary of the material terms of the 2017 Plan is set forth in the Company's definitive proxy statement for the Annual Meeting, which was filed with the Securities and Exchange Commission on April 9, 2025. A copy of the 2017 Plan is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 5.07 Submissions of Matters to a Vote of Security Holders